Resource Facilitation: Indiana Best Practices Manual for Return-to- Work or Return-to-School Click on the read more button to get a link to download the full manual. Once you… Read More
Multicenter Evaluation of Memory Remediation after TBI with Donepezil (MEMRI-TBI-D Study) March 10, 2015 Flora Hammond, MD (PI); Funded by National Institute on Disability and Rehabilitation Research (NIDRR). This study… Read More
New RHI Research Study, seeking participants: Lifestyle Management in Spinal Cord Injury: This pilot study is modeled on a successful lifestyle change program conducted at the University of Pittsburgh. Based… Read More
Flora M. Hammond, M.D. is featured as one of the TBI Model Systems Researchers in the Fall Edition of the Brain Injury Association of America ‘The Challenge’ Publication. Click on… Read More
FOR IMMEDIATE RELEASE October 24, 2014 CONTACT: Stephanie S. Hale, BAA, Marketing Public Relations and Marketing Off.: 317-329-2093 Cell: 317-626-2910 email@example.com Flora M. Hammond, M.D.… Read More
Multicenter Evaluation of Memory Remediation after TBI with Donepezil (MEMRI-TBI-D Study)
March 10, 2015
Flora Hammond, MD (PI); Funded by National Institute on Disability and Rehabilitation Research (NIDRR).
This study is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week trial that will evaluate the effect of donepezil on treatment for functionally important verbal memory problems among 160 individuals (age 18-60 years) who sustained a complicated mild, moderate, or severe non-penetrating TBI six to 36 months prior to study participation.
The primary aims of this study are to evaluate the effect of donepezil on verbal memory and to assess the effects of donepezil on memory-related everyday function in the target population (i.e., persons age 18-60 years with clinically important verbal memory impairments during the subacute or chronic period (i.e., 6-36 months after complicated mild, moderate, or severe non-penetrating TBI). The study also will acquire data that inform on the effects of donepezil on other aspects of cognition (i.e., attention, processing speed, executive function), neuropsychiatric symptoms, community participation, and quality of life in this population as well as on caregiver burden.
Contact: Christy Sargent at firstname.lastname@example.org or at (317) 963-7448